uniQure N.V. (QURE): Net Income
-$198.97M
Year ended 2025-12-31
-$208.87M
Trailing 12 months to 2026-03-31
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$198.97M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$239.56M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$308.48M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$126.79M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $329.59M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$125.02M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$124.20M | n/m | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | -$83.30M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$79.26M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$73.37M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$82.08M | n/a | 2018-03-14, From 2015-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | -$198.97M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$49.59M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$33.50M | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$79.62M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$958.0K | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | -$6.13M | n/m |
| Palatin Technologies Inc (PTN) | 2026-06-30 | -$8.38M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$124.02M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$68.87M | n/m |
Compare QURE, IRD, ABUS, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗